BWM Planning LLC Has $889,000 Stake in Eli Lilly and Company $LLY

BWM Planning LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 10.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,141 shares of the company’s stock after purchasing an additional 112 shares during the quarter. BWM Planning LLC’s holdings in Eli Lilly and Company were worth $889,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. FUKOKU MUTUAL LIFE INSURANCE Co raised its position in shares of Eli Lilly and Company by 33.0% in the second quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 4,900 shares of the company’s stock valued at $3,820,000 after purchasing an additional 1,215 shares during the period. Howe & Rusling Inc. raised its holdings in Eli Lilly and Company by 110.1% in the 2nd quarter. Howe & Rusling Inc. now owns 895 shares of the company’s stock worth $698,000 after acquiring an additional 469 shares during the period. Lionshead Wealth Management LLC lifted its position in Eli Lilly and Company by 4.6% during the 2nd quarter. Lionshead Wealth Management LLC now owns 568 shares of the company’s stock worth $443,000 after acquiring an additional 25 shares during the last quarter. EFG Asset Management Americas Corp. acquired a new position in Eli Lilly and Company during the 2nd quarter worth $5,548,000. Finally, Mizuho Securities Co. Ltd. boosted its holdings in Eli Lilly and Company by 206.7% during the second quarter. Mizuho Securities Co. Ltd. now owns 460 shares of the company’s stock valued at $359,000 after acquiring an additional 310 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LLY. CICC Research lifted their price objective on Eli Lilly and Company from $801.00 to $1,060.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Leerink Partners raised Eli Lilly and Company from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $886.00 to $1,104.00 in a research report on Monday, November 10th. Daiwa Capital Markets upped their price target on Eli Lilly and Company from $700.00 to $940.00 in a report on Monday, November 10th. Morgan Stanley increased their price objective on Eli Lilly and Company from $1,090.00 to $1,171.00 and gave the company an “overweight” rating in a research report on Thursday, November 13th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and seven have given a Hold rating to the company. According to MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,027.95.

Eli Lilly and Company Stock Up 1.8%

Shares of LLY stock opened at $1,048.90 on Thursday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,055.59. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The stock has a fifty day moving average price of $844.09 and a 200 day moving average price of $784.22. The stock has a market cap of $991.61 billion, a P/E ratio of 68.56, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the firm posted $1.18 EPS. The business’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.